ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference LOS ANGELES, Calif., March 26, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 […]
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and Systemic Lupus Erythematosus IMPT-514 is the first-and-only CD19/CD20 CAR T-cell therapy in development for lupus Designed to reset the immune system, IMPT-514 is a one-time treatment option with potential to replace […]
HER2 and HLA-A*02 Dual CAR-T Cells Utilize LOH in a NOT Logic Gate to Address On-Target Off-Tumor Toxicity
ImmPACT Bio is pleased to announce the publication of their work in the Journal of ImmunoTherapy of Cancer regarding NOT logic gated CAR T cells for limiting on-target off-tumor toxicity titled, “HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity”. This work demonstrates that inhibitory CAR […]
ImmPACT Bio Recognized in BioSpace’s 2024 Best Places to Work
ImmPACT Bio Recognized in BioSpace’s 2024 Best Places to Work LOS ANGELES, Calif., November 8, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced it has been named on the BioSpace 2024 Best Places to Work […]
Enhancing TCR-T Responses and Overcoming the Tumor Microenvironment in Combination with a TGFβ-specific CAR
Weist M, et al. Poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. November 2023
